Background {#Sec1}
==========

Arterial hypertension (HTN) is a major cardiovascular risk factor affecting approximately 30--45 % of the general population \[[@CR1], [@CR2]\]. HTN is not only associated with an increased incidence of other risk factors, but also directly contributes to the development and progression of atherosclerotic disease \[[@CR3]\]. Accordingly, patients with myocardial infarction (MI) and a history of HTN are known to be older and to have a higher rate of comorbidities and more extensive atherosclerotic disease than patients with MI but no HTN \[[@CR4]\]. Several studies demonstrated that patients with MI and antecedent HTN are at increased risk for adverse cardiovascular events, such as heart failure, recurrent MI or death \[[@CR4]--[@CR11]\]. However, whether differences in myocardial salvage, infarct size or microvascular injury contribute to the adverse outcome in contemporary reperfused MI patients is unknown. Cardiovascular magnetic resonance (CMR) is the reference technique for the determination of these infarct characteristics \[[@CR12]\], which are known to be strongly correlated with clinical prognosis in patients with ST-elevation MI (STEMI) reperfused by primary percutaneous coronary intervention (PPCI) \[[@CR13]--[@CR16]\].

The aim of this study was therefore to assess the association of antecedent HTN with myocardial salvage and damage determined by CMR as well as to evaluate its prognostic significance on adverse clinical events in a large multicenter cohort of consecutive patients treated with PPCI for STEMI.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

This was an analysis of data from the multicenter CMR substudy of the AIDA STEMI trial (Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction; NCT00712101). The rationale, design and main results of AIDA STEMI as well as its CMR substudy have been reported elsewhere \[[@CR15], [@CR17]--[@CR20]\]. Briefly, AIDA STEMI randomized 2065 consecutive STEMI patients treated within 12 h after symptom onset to either intracoronary or intravenous abciximab bolus (0.25 mg/kg) during PPCI with a subsequent 12 h dose-adjusted intravenous infusion. The CMR substudy enrolled 795 patients at 8 sites with proven expertise in CMR imaging, which was performed within 10 days after infarction. Importantly, there was no difference in CMR parameters of myocardial salvage and damage between both treatment groups \[[@CR20]\]. The presence of antecedent arterial HTN was prospectively questioned and hypertension was diagnosed if patients were on antihypertensive treatment or had ≥3 systolic blood pressure values \>140 mmHg on at least two different days. Patients were categorized as having antecedent HTN or not. Major adverse cardiac events (MACE), defined as a composite of all-cause death, nonfatal re-MI and new congestive heart failure, were recorded at 12 months after STEMI. Detailed endpoint definitions have been published previously \[[@CR17]\]. The local ethics committees approved the study and all patients gave a written informed consent.

Cardiovascular magnetic resonance {#Sec4}
---------------------------------

Patients were examined at rest in the supine position on 1.5 or 3.0 Tesla scanners at day 1 to 10 after STEMI. Standardized imaging sequences were used as described previously \[[@CR17], [@CR20], [@CR21]\]. Blinded readers performed image analysis at the CMR core laboratory (University of Leipzig - Heart Center, Leipzig, Germany). Commercially available software was used for post-processing (cmr42, Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada). The core laboratory has proven excellent reproducibility and low inter- as well as intra-observer variability in patients with acute STEMI \[[@CR22]\]. Measurements of the area-at-risk, infarct size, and microvascular obstruction were expressed as the percentage of left ventricular (LV) volume (%LV). Myocardial salvage index was determined from area at risk and infarct size as previously described \[[@CR13]\]. As described previously \[[@CR20]\], LV function was available for 792 patients. Late gadolinium enhancement (LGE) for the determination of infarct size and microvascular obstruction was available in 774 patients. T2-weighted imaging for the assessment of the area-at-risk was available for 695 patients. The prevalence of incomplete CMR scans was not significantly different between patients with or without antecedent HTN.

Statistical analysis {#Sec5}
--------------------

Since most of the continuous variables were non-normally distributed, all continuous data were expressed as median with interquartile range for reasons of uniformity. Categorical data were depicted as counts and percentage. Distribution of data was tested using the Shapiro-Wilk test. Testing for differences between groups was performed with Mann--Whitney-*U* test or Kruskal-Wallis test for continuous variables and *x* ^2^-test for categorical variables. To identify predictors of infarct size, microvascular obstruction, myocardial salvage index, and left ventricular ejection fraction, multiple linear regression analysis was performed. Outcome functions were assessed using Kaplan-Meier graphs with log-rank comparison between groups. In addition, univariate and multivariate Cox regression analysis was performed to identify predictors for time to MACE. Multivariate analysis was performed using variables with a *p* \< 0.05 in univariate analysis. All variables listed in Table [1](#Tab1){ref-type="table"} were assessed in univariate analysis (except the TIMI risk score). Tests were two-tailed, and a probability value of \<0.05 was considered statistically significant. All analyses were performed using SPSS version 22.0.0 (IBM, Armonk, NY, USA).Table 1Baseline characteristicsAll patients (*n* = 792)Hypertension (*n* = 540)No hypertension (*n* = 252)*p* valueAge, years62 \[51--71\]66 \[55--73\]54 \[48--63\]\<0.001Male sex, n (%)600 (76)389 (72)211 (84)\<0.001Body mass index, kg/m^2^27 \[25--30\]28 \[25--31\]26 \[24--29\]\<0.001Cardiovascular risk factors Current smoking, n (%)339/724 (43)194/482 (36)145/242 (58)\<0.001 Diabetes mellitus, n (%)160/789 (20)142/539 (26)18/250 (7)\<0.001 Hypercholesterolemia, n (%)303/784 (38)250/536 (46)53/250 (21)\<0.001 Family history for CAD, n (%)268/611 (34)177/407 (33)91/204 (36)0.79Systolic blood pressure, mmHg130 \[117--147\]135 \[119--150\]126 \[114--140\]\<0.001Diastolic blood pressure, mmHg80 \[70--88\]80 \[70--90\]80 \[70--85\]0.07Heart rate, beats/min76 \[67--87\]76 \[68--88\]76 \[65--85\]0.23Time from symptom onset to PCI hospital admission, min180 \[109--310\]183 \[110--311\]166 \[104--306\]0.23Door-to-balloon time, min30 \[22--42\]30 \[23--42\]29 \[20--42\]0.56Previous infarction, n (%)48/791 (6)42/539 (8)6/631 (2)\<0.01Previous PPCI, n (%)67 (9)61 (11)6 (2)\<0.001Previous CABG, n (%)11 (1)11 (2)0 (0)0.02Anterior infarction, n (%)395/755 (50)262/516 (49)133/239 (53)0.21Killip-class on admission0.52 1, n (%)696 (88)472 (87)224 (89) 2, n (%)59 (7)42 (8)17 (7) 3, n (%)20 (3)16 (3)4 (2) 4, n (%)17 (2)10 (2)7 (3)Number of diseased vessels\<0.01 1, n (%)419 (53)261 (48)158 (63) 2, n (%)225 (28)165 (31)60 (24) 3, n (%)148 (19)114 (21)34 (14)Infarct related artery0.59 Left anterior descending, n (%)344 (43)240 (44)104 (41) Right coronary artery, n (%)344 (43)226 (42)118 (47) Left circumflex, n (%)97 (12)68 (13)29 (12) Left main, n (%)5 (1)4 (1)1 (0) Bypass graft, n (%)2 (0)2 (0)0 (0)TIMI risk score3 \[2--5\]4 \[2--5\]2 \[2--4\]\<0.001TIMI-flow before PPCI0.64 TIMI-flow 0, n (%)444 (56)298 (55)146 (58) TIMI-flow 1, n (%)103 (13)73 (14)30 (12) TIMI-flow 2, n (%)128 (16)92 (17)36 (14) TIMI-flow 3, n (%)117 (15)77 (14)40 (16)TIMI-flow after PPCI0.38 TIMI-flow 0, n (%)12 (2)9 (2)3 (1) TIMI-flow 1, n (%)19 (2)14 (3)5 (2) TIMI-flow 2, n (%)61 (8)47 (9)14 (6) TIMI-flow 3, n (%)699 (88)469 (87)230 (91)Stent implanted, n (%)774 (98)527 (98)247 (98)0.60Thrombectomy, n (%)190 (24)124 (23)66 (26)0.32Concomitant medications Aspirin, n (%)790 (100)538 (100)252 (100)1.0 ß-blockers, n (%)757 (96)519 (96)238 (94)0.19 ACE-I/ARB, n (%)751 (95)515 (95)236 (94)0.21 Statin, n (%)749 (95)508 (94)241 (96)0.47 Aldosterone antagonist, n (%)80 (10)55 (12)25 (10)0.34Data are given as median plus interquartile range or number and percentage*Abbreviations*: *CAD* coronary artery disease, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIMI* thrombolysis in myocardial infarction, *ACE-I* angiotensin converting enzyme inhibitor, *ARB* angiotensin receptor blocker

Results {#Sec6}
=======

Study population {#Sec7}
----------------

Between July 2008 and April 2011 795 STEMI patients were enrolled in the CMR substudy of the AIDA STEMI trial. Information on antecedent HTN was available in 792 (99.6 %) patients, representing the final study cohort. Characteristics of the overall cohort as well as stratified by history of HTN are listed in Table [1](#Tab1){ref-type="table"}. Antecedent HTN was associated with more advanced age, a higher body mass index, a higher prevalence of female sex, diabetes mellitus, hypercholesterolemia (*p* \< 0.001 respectively), multivessel disease (*p* \< 0.01), and previous myocardial infarction (*p* \< 0.01), but a lower prevalence of current smoking (*p* \< 0.001). HTN was also associated with a higher systolic blood pressure on admission (*p* \< 0.001) and a trend for a higher diastolic blood pressure (*p* = 0.07) with no significant difference in heart rate (*p* = 0.23). Pre- and post-PPCI TIMI-flow were equal in both groups (*p* = 0.64 and *p* = 0.38, respectively).

Antecedent hypertension and clinical outcome {#Sec8}
--------------------------------------------

During the follow-up period of 12 months, 53 patients (7 %) experienced MACE. Of these 22 (3 %) died. Patients with antecedent HTN were at higher risk for MACE (45 \[8 %\] versus 8 \[3 %\], *p* \< 0.01; hazard ratio: 2.70 \[1.27--5.72\], *p* = 0.01) and mortality (20 \[4 %\] versus 2 \[1 %\], *p* = 0.02; hazard ratio: 4.83 \[1.13--20.67\], *p* = 0.03) as compared to patients without antecedent HTN (Table [2](#Tab2){ref-type="table"}). Consequently, antecedent HTN showed a significant association with MACE- and mortality-free survival (*p* \< 0.01 and *p* = 0.02, respectively, Fig. [1](#Fig1){ref-type="fig"}). In multivariate Cox regression analysis, antecedent HTN was independently associated with the occurrence of MACE (Table [3](#Tab3){ref-type="table"}). In a second Cox regression model including established CMR prognosis markers (left ventricular ejection fraction, infarct size, microvascular obstruction), antecedent HTN was also independently associated with MACE after 12 months (hazard ratio: 2.55 \[1.20--5.43\], *p* = 0.02). 339 (43 %) of patients had HTN at the time of the acute event (defined as systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg). In contrast with antecedent HTN, HTN at the time of the acute event was not significantly associated with the rate of MACE (log-rank *p* = 0.18).Table 2Event rates at 12 months after infarctionAll patients (*n* = 792)Hypertension (*n* = 540)No hypertension (*n* = 252)*p* valueMACE, n (%)53 (7)45 (8)8 (3)\<0.01Death, n (%)22 (3)20 (4)2 (1)0.02Re-infarction, n (%)21 (3)16 (3)5 (2)0.42Heart failure event, n (%)25 (3)21 (4)4 (2)0.08Data are given as number and percentage*Abbreviations*: *MACE* major adverse cardiac events Fig. 1Kaplan-Meier curves for the occurrence of major adverse cardiac events and death according to antecedent hypertension Table 3Predictors of MACE in uni- and multivariate Cox regression analysisUnivariateMultivariateHR (95 % CI)*p* valueHR (95 % CI)*p* valueAge, \>median2.49 \[1.38--4.47\]\<0.01\--Gender, 1 female1.95 \[1.12--3.40\]0.02\--Smoking status, 1 yes0.46 \[0.24--0.87\]0.02\--Diabetes mellitus, 1 yes1.91 \[1.07--3.41\]0.03\--Hypertension, 1 yes2.70 \[1.27--5.72\]0.013.42 \[1.45--8.08\]\<0.01Heart rate, \>median1.96 \[1.12--3.43\]0.02\--Killip-class, I-IV1.90 \[1.46--2.48\]\<0.0011.91 \[1.40--2.60\]\<0.001Vessel Disease, I-III1.34 \[1.01--1.78\]0.04\--Uni- and multivariate Cox regression analysis for the prediction of MACE at 12 months after infarction. Only significant variables in univariate analysis are reported*Abbreviations*: *MACE* major adverse cardiac events, *HR* hazard ratio, *CI* confidence interval

Antecedent hypertension and cardiovascular magnetic resonance findings {#Sec9}
----------------------------------------------------------------------

The median time between the index event and CMR scan was 3 \[[@CR2]--[@CR4]\] days. CMR findings and their relation with antecedent HTN are shown in Table [4](#Tab4){ref-type="table"}. Patients with antecedent HTN had a similar extent of the area at risk (*p* = 0.18), infarct size (*p* = 0.74), microvascular obstruction (*p* = 0.93), and a comparable myocardial salvage index (0.20). There was also no significant difference in left ventricular ejection fraction between groups (*p* = 0.47). Antecedent HTN was not predictive for infarct size, microvascular obstruction, myocardial salvage index or left ventricular ejection fraction at linear regression analyses (all *p* \> 0.05). The power of this study to exclude a difference in infarct size or LV ejection fraction of 3 % between groups is 94.9 and 98.5 %, respectively.Table 4Cardiovascular magnetic resonance findingsAll patients (*n* = 792)Hypertension (*n* = 540)No hypertension (*n* = 252)*p* valueArea at risk, % LV35 \[25--48\]34 \[25--47\]37 \[26--49\]0.18Infarct size, % LV16.7 \[8.5--24.9\]16.9 \[8.8--24.8\]16.6 \[8.3--25.0\]0.74Presence of microvascular obstruction, n (%)400 (51)274 (51)126 (50)0.85Extent of microvascular obstruction, % LV0 \[0--1.8\]0 \[0.0--1.6\]0 \[0.0--2.0\]0.93Myocardial salvage index, % area at risk51 \[33--69\]50 \[33--67\]54 \[32--72\]0.20LV ejection fraction, %50 \[43--58\]50 \[43--58\]51 \[44--58\]0.47LV myocardial mass, g132 \[109--156\]134 \[111--158\]131 \[109--155\]0.38Data are given as median plus interquartile range or number and percentage*Abbreviations*: *CMR* cardiovascular magnetic resonance, *LV* left ventricular

Discussion {#Sec10}
==========

This is the first study evaluating the impact of antecedent HTN on CMR parameters of myocardial salvage as well as myocardial and microvascular damage in patients undergoing PPCI for acute STEMI. There are two main findings: (1) antecedent HTN was independently associated with a higher rate of MACE and mortality at 12-month follow-up; (2) however, there were no differences in CMR-determined myocardial salvage, infarct size or extent of microvascular obstruction between patients with or without antecedent HTN. Together, these findings highlight the importance of a history of HTN as risk factor of adverse outcome in contemporary reperfused STEMI patients, which is however not attributed to differences in PPCI efficacy (myocardial salvage), extent of myocardial necrosis or microvascular injury as visualized by CMR.

Antecedent hypertension, baseline risk profile and clinical outcome {#Sec11}
-------------------------------------------------------------------

As a consequence of its well established role as a major cardiovascular risk factor \[[@CR1]\], antecedent HTN is a frequent finding in MI patients. In our analysis, history of HTN was present in 68 % of STEMI patients. These results fit well with recent prospective STEMI registry studies which reported a prevalence between 60 and 70 % \[[@CR23], [@CR24]\]. Antecedent HTN has been acknowledged as significant risk factor for adverse outcome in survivors of acute MI for many years \[[@CR4]--[@CR6]\]. For instance, Thune et al. found that antecedent HTN at the time of MI was strongly associated with an increased risk of future heart failure, stroke, cardiovascular death and a composite endpoint consisting of death, myocardial infarction, heart failure, stroke, or cardiac arrest in more than 14.000 patients included in the VALIANT trial (Valsartan in Myocardial Infarction Trial) \[[@CR4]\]. Nevertheless, over the last years, reperfusion strategies and pharmacological interventions were significantly refined and consequently improved the outcome of patients presenting with acute MI \[[@CR25]\]. These advances might have modified the relationship between HTN and the clinical course after STEMI \[[@CR26]\]. Indeed, in a meta-analysis performed by Chen et al. the strength of the association between antecedent HTN and poor clinical outcome has decreased over time \[[@CR11]\]. However, antecedent HTN was still associated with increased MACE and mortality rates at 12-month follow-up in our study. This was also observed after adjustment for confounding variables. Therefore, our findings highlight that even in the contemporary era of PPCI the simple information of HTN history can be used to identify patients at risk for adverse prognosis post-STEMI. This high risk group might also benefit from more intensified medical treatment strategies including aggressive antihypertensive treatment. Contrary to the information on antecedent HTN, HTN at the time of the acute event was not related with MACE in our study. Consequently, antecedent HTN seems of greater importance as compared with HTN at the time of STEMI.

It is well established that MI patients with a history of HTN show a distinctive baseline risk profile, irrespective of STEMI or non-STEMI presentation. Studies consistently observed that hypertensive patients with MI were older, more often female, had a higher body mass index, and higher rates of other cardiovascular risk factors including diabetes or hypercholesterolemia \[[@CR6]--[@CR10]\]. Our data confirm these previous findings and it is likely that these factors might at least partly explain the higher risk of hard clinical events of hypertensive STEMI patients. Further observations from our and other studies are the higher incidence of a previous cardiac disease and the greater extent of coronary artery disease \[[@CR4], [@CR7], [@CR9], [@CR10]\]. Since both have been proved to be associated with adverse clinical outcome in STEMI patients \[[@CR27]\], these factors might also contribute to the increased risk of infarction patients with antecedent HTN. Recent studies could also disclose that diffuse myocardial fibrosis, measured by T1 mapping, is increased in patients with hypertension and previous infarction \[[@CR28]\].

Antecedent hypertension and infarct characteristics {#Sec12}
---------------------------------------------------

It has been speculated that coronary occlusion in patients with pre-existing HTN might be associated with more extensive myocardial damage, greater myocardial dysfunction, and consequently adverse clinical outcome \[[@CR11], [@CR26]\]. Contrary, one might argue that a higher diastolic pressure could enhance coronary perfusion and collateral circulation with subsequently improved efficacy of reperfusion and limited expansion of myocardial necrosis. Studies investigating the impact of antecedent HTN on myocardial damage are very limited so far \[[@CR29]\]. In particular, there is no study answering these questions by using the current reference standard technique, which is CMR \[[@CR12]\]. CMR not only enables exact infarct sizing but also detailed tissue characterization of the jeopardized and infarcted myocardium \[[@CR12]\]. These additional assessed parameters, primarily microvascular obstruction, but also myocardial salvage index provide strong prognostic information that is incremental to clinical, biomarker, electrocardiographic, and angiographic risk markers \[[@CR15], [@CR30]\]. To the best of our knowledge, the study by De Luca et al. \[[@CR29]\]. is the first and only study that evaluated the impact of HTN on infarct size in 830 STEMI patients undergoing PPCI. The authors found that HTN was not associated with larger infarcts as determined by scintigraphy at 1 month after infarction. Nevertheless, some important limitations of this study have to be mentioned. The authors used a scintigraphic technique to assess infarct size, which is less accurate compared to CMR, especially for the detection of subendocardial infarcts \[[@CR31]\]. Secondly, De Luca et al. were also not able to assess the association of antecedent HTN with myocardial salvage and microvascular dysfunction. Our study therefore complements and extends the previous literature by showing for the first time that the adverse outcome of reperfused STEMI patients with antecedent HTN is not associated with differences in reperfusion success or more pronounced myocardial injury.

Limitations {#Sec13}
-----------

Our study has some important limitations. Based on the in- and exclusion criteria of this multicenter clinical trial as well as the treatment of patients in specialized high-volume centers, our results might not be generalizable to all STEMI populations. Although AIDA STEMI was designed as all-comers trial to represent a "real-world" STEMI population \[[@CR18], [@CR20]\], further confirmation of our findings in other studies would be important. It is, however, important to note that the power of our study to exclude a 3 % difference in infarct size or LV ejection fraction between groups was approximately 95 %. Information on HTN was based on patient history and data on the duration of HTN as well as patients adherence to medication and effectiveness of HTN treatment, which could have prognostic implications as well, was not available. Nevertheless, our study shows that the simple assessment of antecedent HTN by anamnesis or during hospitalization has strong prognostic implications in STEMI patients treated with PPCI. Forty-eight patients (6 %) had a previous myocardial infarction. Chronic infarcts were not included in infarct size measurements and thus the "true volume" of the infarcted myocardium is not represented in the reported values. On the other hand, omitting those patients from statistical analysis did not significantly change the results.

Conclusion {#Sec14}
==========

This study found higher rates of MACE and mortality in contemporary reperfused STEMI patients with antecedent HTN despite no difference in reperfusion success and extent of myocardial and microvascular damage as determined by CMR.
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